CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

NCT03163667 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG: Placebo
DRUG: CB-839
DRUG: everolimus

Sponsor

Calithera Biosciences, Inc